Clinical trial NCT00744276 - References

Fibrocystic Disease of Breast — A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease

Citation(s)

•   Barbieri RL
  Danazol: molecular, endocrine, and clinical pharmacology. Prog Clin Biol Res. 1990;323:241-52. Review.
•   Gateley CA, Mansel RE
  Management of cyclical breast pain. Br J Hosp Med. 1990 May;43(5):330-2.
•   Gledhill JM, Barker S, Wanless C, Hinson JP, Puddefoot JR, Panahy C, Goode AW, Vinson GP
  Progesterone receptor induction by danazol in cultured cancer cells and the rat uterus. J Steroid Biochem Mol Biol. 1992 Oct;43(4):289-96.
•   Gumm R, Cunnick GH, Mokbel K
  Evidence for the management of mastalgia. Curr Med Res Opin. 2004 May;20(5):681-4. Review.
•   Hughes LE, Mansel RE, Webster DJ
  Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet. 1987 Dec 5;2(8571):1316-9.
•   Panahy C, Puddefoot JR, Anderson E, Vinson GP, Berry CL, Turner MJ, Brown CL, Goode AW
  Effects of danazol on incidence of progesterone and oestrogen receptors in benign breast disease. Br Med J (Clin Res Ed). 1987 Aug 22;295(6596):464-6.
•   Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P
  Benign breast disease I: hormonal investigation. Obstet Gynecol. 1979 Apr;53(4):457-60.
•   Vaidyanathan L, Barnard K, Elnicki DM
  Benign breast disease: when to treat, when to reassure, when to refer. Cleve Clin J Med. 2002 May;69(5):425-32.
•   Wang DY, Fentiman IS
  Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat. 1985;6(1):5-36. Review.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease

Details for clinical trial NCT00744276